cheshtasharma

About Cheshta Sharma

This author has not yet filled in any details.
So far Cheshta Sharma has created 1323 blog entries.

Is Drugs and Cosmetics act-a link with Indian patent act?

It is an interesting case where Bayer Corporation, instead of filing a suit for infringement, filed an inventive writ petition in the Delhi High Court desiring that since the applications of Cipla “SORANIB” allegedly infringed its patent, according to Drugs and Cosmetics act Cipla’s marketing approval application should not even be processed or entertained. [...]

By |2017-09-08T18:35:20+05:30November 18th, 2016|Patent|0 Comments

Australian patent for New superbug test developed by TGen-NAU

The Translational Genomics Research Institute (TGen), is a non-profit genomics research institute established in 2002 by Jeffrey Trent, the founding Scientific Director of the National Human Genome Research Institute (NHGRI), in Phoenix, Arizona, United States along with Northern Arizona University (NAU) developed a technology to identify an Antibiotic- resistant infections which is protected under [...]

By |2017-09-08T18:36:43+05:30November 18th, 2016|Patent|0 Comments

Who won the case for Nexium infringement?

This case involves the same verdict of Patent infringement as AstraZeneca sued on various Pharmaceutical companies, and this case is the fight for Nexium which is a drug used in treatment of GERD. Since, AstraZeneca received a notice saying that Zydus had filed an abbreviated new drug application(ANDA) with the U.S. Food and Drug [...]

By |2017-09-08T18:38:06+05:30November 18th, 2016|Patent|0 Comments

Did AstraZeneca hit the Case against Mylan for Faslodex?

AstraZeneca owns a patent for Faslodex, with U.S. Patent Nos. 6,774,122, 7,456,160, 8,329,680, and 8,466,139.Which has the chemical name fulvestrant, used in the treatment of breast cancer for post-menopausal women who have not responded to any other hormonal therapies. AstraZeneca alleges the complaint against Mylan for filing the abbreviated new drug application recently with U.S. Food and Drug [...]

By |2017-09-08T18:38:52+05:30November 18th, 2016|Patent|0 Comments

Why Astra Zeneca sue Mylan for a “blood thinning agent”

Brilinta is a blood thinner used in the treatment of coronary heart disease, angina pectoris which is commonly called as heart attack. Brilinta prevents the blood clots and maintains the blood flow in the body to help reduce the risk of another cardiovascular event. AstraZeneca is a London-based pharmaceutical company, who owns five patents [...]

By |2017-09-08T18:41:17+05:30November 18th, 2016|IP Basics|0 Comments

Professor Whitaker after facing lot of plagiarism issues resigns from ASU

Plagiarism is the term that still remains unclear, "wrongful appropriation" and "stealing and publication" of another author’s "language, thoughts, ideas, or expressions" and the representation of them as one's own original work. The concept of plagiarism emerged in Europe in the 18th century. The idea remains problematic with unclear definitions and unclear rules. The modern concept of [...]

By |2017-09-08T18:42:36+05:30November 18th, 2016|India|0 Comments
Go to Top